According to NBC Nightly News, hundreds of Americans are going after the GLP-1 drugmakers Novo Nordisk and Eli Lilly and Company. Novo manufactures Ozempic and Wegovy while Eli Lilly makes Zepbound.
As for why, The Wall Street Journal reports a doctor told 53-years-old Michelle Fennell that she was diagnosed with a vision loss condition called NAION and told her immediately stop taking Ozempic for her Type 2 diabetes. She was shocked by the news as she only started taking the drug six months ago.
While new scientific research finds that certain GLP-1s has an increased risk of NAION, there is not enough evidence to suggest the condition is cause by the drug. And the Food and Drug Administration (FDA) is currently investigating but won’t do anything until after the assessment.
Countries other than the U.S. have persuaded Novo and Eli Lilly to include a warning on their label.
Houston physician Dr. Mary Talley Bowden talked about this on American Family Radio (AFR)'s “Jenna Ellis in the Morning” program.
“It looks like what's happening is basically a little stroke to the eye. The blood supply is getting cut off to the eye. It is rare... but about 10% of the population is actually on these drugs. Even more concerning, though, is children are being put on these drugs now,” Bowden says.
She warned that unknown risks often emerge only after drugs hit the market.
Show Host Jenna Ellis noted that society’s rush for an easy shortcut often bypasses hard lifestyle changes — and traditional medical caution.
“The whole point and the lesson, I think, that we learned after COVID was that we need to be able to advocate for ourselves and ultimately determine what is best for ourselves and our family,” Ellis says.
As food recalls and health mandates continue to drive public skepticism, medical experts urge patients to ask tougher questions before filling that next prescription.
